Fidelity Investments’s OnKure Therapeutics OKUR Stock Holding History

Fidelity Investments’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$1.16K	–	5601
2025 Q4	$1.16K	Buy	400 +350	+700%	+$1.05K	﹤0.01%	5082
2025 Q3	$138	Buy	+50	New	+$124	﹤0.01%	5180
2024 Q3	–	Sell	-1,262	Closed	-$19.1K	–	5767
2024 Q2	$19.1K	Buy	1,262 +1,101	+684%	+$18.7K	﹤0.01%	4088
2024 Q1	$2.66K	Buy	161 +143	+794%	+$2.36K	﹤0.01%	4645
2023 Q4	$286	Sell	18 -18	-50%	-$1.12K	﹤0.01%	4850
2023 Q3	$2.76K	Buy	36 +30	+500%	+$2.04K	﹤0.01%	4463
2023 Q2	$420	Buy	+6	New	+$483	﹤0.01%	4834
2022 Q2	–	Sell	-629	Closed	-$18K	–	5581
2022 Q1	$18K	Sell	629 -3,041	-83%	-$170K	﹤0.01%	4058
2021 Q4	$314K	Sell	3,670 -15,080	-80%	-$1.11M	﹤0.01%	2879
2021 Q3	$1.4M	Hold	18,750	–	–	﹤0.01%	2638
2021 Q2	$1.75M	Buy	+18,750	New	+$2.09M	﹤0.01%	2577

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments's OKUR Position: Q1 2026 in Review

Fidelity Investments sold out of OnKure Therapeutics (OKUR) in Q1 2026, closing a stake of 400 shares — an estimated $1.16K sold.

Fidelity Investments first reported a position in OKUR in Q2 2021 and held it in 11 quarters. The position peaked at $1.75M in Q2 2021. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

Fidelity Investments reported no remaining OnKure Therapeutics position as of Q1 2026 after selling out during the quarter.
Fidelity Investments sold 400 OnKure Therapeutics shares in Q1 2026, an estimated $1.16K.
Fidelity Investments first reported a position in OnKure Therapeutics in Q2 2021 and held it in 11 quarters.
Fidelity Investments's OnKure Therapeutics position peaked at $1.75M in Q2 2021.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.